Vertex Pharmaceuticals Incorporated (VRTX)

Analysts 5
Positive
100%
Median target $184 (18% upside)


    • 10/18/17
      RBC Capital
      outperform
      $181
    • 09/29/17
      D.A. Davidson
      buy
      $200
    • 09/28/17
      BTIG Research
      buy
      $200
    • 07/27/17
      JP Morgan
      overweight
      $184
      "While Kalydeco and Orkambi continue to beat expectations we are overwhelmingly focused on..."
      View details
    • 07/27/17
      BMO Capital Markets
      outperform
      $182
    • 07/19/17
      Morgan Stanley
      overweight
      $190
    • 07/19/17
      Credit Suisse
      outperform
      $195
    • 07/19/17
      Robert W. Baird
      outperform
      $171
    • 07/19/17
      Needham & Company
      buy
      $195
      "...impressive data in homozygous F508 patients were reported w/ 7.3 to 9.5 percentage point..."
      View details
    • 07/19/17
      Janney Montgomery Scott
      buy
    • 07/19/17
      Jefferies
      buy
      $185
    • 07/19/17
      Citigroup
      buy
      $190
      "We raised the probability of triple combo therapy in het-min CF patients from 50% to 100% given..."
      View details
    • 07/19/17
      Raymond James
      outperform
      $181
    • 07/19/17
      Barclays
      overweight
      $180
    • 07/19/17
      Stifel Nicolaus
      buy
      $182
      "No doubt about it Vertex triple data exceeded our Street and KOL expectations on both efficacy..."
      View details
    • 07/19/17
      Cowen
      outperform
      $200
      "Efficacy data from VRTX's triple regimens showed breakthrough-quality results with approx. 10..."
      View details
    • 07/19/17
      Maxim Group
      buy
      $195
      "Based on the triple combination(s) we have increased the market share in the heterozygote..."
      View details
    • 07/19/17
      UBS
      neutral
      $174
    • 06/22/17
      Leerink Swann
      outperform
      "The current rally reflects the lifting of perceived fears of pricing regulations and a favorable..."
      View details
    • 06/02/17
      Oppenheimer
      outperform
      $150
      "...we believe there is a ~70% chance that the impending Phase 1 and Phase 2 triplet data will be..."
      View details
    • 05/18/17
      Bank of America Merrill Lynch
      neutral
      $125
    • 05/18/17
      JMP Securities
      market outperform
      $127
    • 03/30/17
      H.C. Wainwright
      neutral
      $85
      "Overall despite management’s highlighting that the new results are strong we beg to differ...."
      View details
    • 11/01/16
      William Blair
      market perform
    • 04/28/16
      Goldman Sachs
      neutral
    • 03/28/16
      Guggenheim
      buy
      $114
    • 03/09/16
      Piper Jaffray
      overweight
      $131
    • 02/04/16
      Argus
      buy
      $140
    • 09/15/15
      Nomura
      buy
      $162
      "We believe Vertex is building a dominant cystic fibrosis franchise with multiple therapies to..."
      View details
    • 07/31/15
      Deutsche Bank
      buy
      $155
    • 06/05/15
      Canaccord Genuity
      buy
      $150
      "Investors have long awaited news on the Vertex biz-dev front. They finally got it and we like the..."
      View details
    • 03/19/15
      Zacks
      neutral
      $136
    • 11/06/14
      CRT Capital
      buy
      $175
    • 10/13/14
      Wells Fargo
      outperform
      $125
    • 07/09/14
      TheStreet
      hold
    • 06/25/14
      Sanford C. Bernstein
      market perform
      $107
    • 04/21/14
      Ned Davis Research
      neutral
    • 03/03/14
      Thomson Reuters/Verus
      buy
    • 10/30/13
      Summer Street
      neutral
    • 100% positive
      $184 Median

    Best rated in Biotechnology last 7 days

    more

    Users who viewed VRTX also viewed

    more

    Best rated stocks last 7 days

    more

    Most rated stocks last 72 hrs

    more